Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCG2 | Q9UNQ0 | 18/20 | 0.80 |
| ▸ | ABCB1 | P08183 | 8/20 | 0.80 |
| ▸ | ABCC1 | P33527 | 4/20 | 0.80 |
| ▸ | MEN1 | O00255 | 3/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.65 |
| ▸ | PDE5A | O76074 | 1/20 | 0.64 |
| ▸ | GAA | P10253 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22273241 | 0.89 | ABCG2 (1.00) | ABCG2ABCB1ABCC1MEN1KMT2A | |
| SCHEMBL29126710 | 0.85 | ABCG2 (0.61) | ABCG2ABCB1ABCC1MEN1KMT2A | |
| SCHEMBL6001975 | 0.83 | ABCG2 (0.88) | ABCG2ABCB1ABCC1MEN1KMT2A | |
| SCHEMBL6001931 | 0.82 | ABCG2 (0.93) | ABCG2ABCB1ABCC1MEN1KMT2A | |
| SCHEMBL16404295 | 0.82 | ABCG2 (1.00) | ABCG2ABCB1ABCC1MEN1KMT2A | |
| SCHEMBL16404294 | 0.80 | ABCG2 (0.86) | ABCG2ABCB1ABCC1MEN1KMT2A | |
| SCHEMBL1064726 | 0.80 | ABCG2 (1.00) | ABCG2ABCB1ABCC1MEN1KMT2A | |
| SCHEMBL5801597 | 0.80 | ABCG2 (0.82) | ABCG2ABCB1ABCC1MEN1KMT2A | |
| SCHEMBL2232116 | 0.79 | ABCG2 (0.81) | ABCG2ABCB1ABCC1MEN1KMT2A | |
| SCHEMBL1063481 | 0.79 | ABCG2 (1.00) | ABCG2ABCB1MEN1KMT2APDE5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080207614-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY | SK CHEMICALS CO., LTD. (KR) | 2008-08-28 | — | — | US | claimed |
| JP-2008526734-A | — | — | 2008-07-24 | — | — | JP | claimed |
| EP-1844023-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY | SK CHEMICALS CO., LTD. (KR) | 2007-10-17 | — | — | EP | claimed |
| WO-2006071095-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY | SK CHEMICALS CO., LTD. (KR) | 2006-07-06 | — | — | WO | claimed |
| US-20080207614-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY | SK CHEMICALS CO., LTD. (KR) | 2008-08-28 | — | — | US | disclosed |
| EP-1844023-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY | SK CHEMICALS CO., LTD. (KR) | 2007-10-17 | — | — | EP | disclosed |
| WO-2006071095-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY | SK CHEMICALS CO., LTD. (KR) | 2006-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207614-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY | GPR119, GCKR, GLP1R | ABCG2 207/4885ABCB1 633/4885ABCC1 510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.